Genomic and Precision Medicine Oncology Third Edition
Family health history and health risk assessment in oncology
Publication
, Chapter
Orlando, LA; Wu, RR
January 1, 2022
Health risk assessments (HRAs) have the potential to play a key role in cancer prevention and early detection both at an individual and a population level. While the idea has been around since the 1950s and HRAs are commonly performed in the workplace, they have not been as readily adopted by the US healthcare system. Several challenges must be addressed before broader uptake of cancer risk assessments in clinical care can occur: (1) usability for providers, (2) usability for patients, (3) quality of patient-entered data, and (4) evidence of impact on health outcomes. In this chapter, we describe recent developments in HRA design that are aimed at addressing these issues.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Orlando, L. A., & Wu, R. R. (2022). Family health history and health risk assessment in oncology. In Genomic and Precision Medicine Oncology Third Edition (pp. 71–83). https://doi.org/10.1016/B978-0-12-800684-9.00021-6
Orlando, L. A., and R. R. Wu. “Family health history and health risk assessment in oncology.” In Genomic and Precision Medicine Oncology Third Edition, 71–83, 2022. https://doi.org/10.1016/B978-0-12-800684-9.00021-6.
Orlando LA, Wu RR. Family health history and health risk assessment in oncology. In: Genomic and Precision Medicine Oncology Third Edition. 2022. p. 71–83.
Orlando, L. A., and R. R. Wu. “Family health history and health risk assessment in oncology.” Genomic and Precision Medicine Oncology Third Edition, 2022, pp. 71–83. Scopus, doi:10.1016/B978-0-12-800684-9.00021-6.
Orlando LA, Wu RR. Family health history and health risk assessment in oncology. Genomic and Precision Medicine Oncology Third Edition. 2022. p. 71–83.